Kopran Ltd
Kopran Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY 2026-27 revenue from operations: Rs. Q1 FY 2026-27 Figures (Rs.
From Kopran Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY 2026-27 revenue from operations: Rs. 15,399 Lakhs (Page 5)
- Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5)
- Year-on-year growth in revenue (Q1): Rs. 15,399 Lakhs vs Rs. 13,522 Lakhs, approx. 14% increase
- Sales/Other Income FY 2025-26: Rs. 68,177 Lakhs; Q1 FY 2026-27: Rs. 15,605 Lakhs (Page 20)
- Formulations segment Q1 FY 2026-27 revenue: Rs. 5,709 Lakhs (Page 9-10)
- APIs segment Q1 FY 2026-27 revenue: Rs. 9,538 Lakhs (Page 8)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Kopran Ltd Q1 FY27 results?
Q1 FY 2026-27 revenue from operations: Rs. Q1 FY 2026-27 Figures (Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Development of an API and R&D facility at Panoli (Gujarat) is mentioned under strategic imperatives (Page 15). - No specific capex amounts, status updates, or precise timelines for capacity expansions or new plants/projects are stated in the presentation. - Emphasis on process improvements, improving yields, and atomization of packing lines in formulations indicate operational enhancements but without specific capex figures or deadlines (Page 15).
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.